Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.

Armstrong, Amy E; Belzberg, Allan J; Crawford, John R; Hirbe, Angela C; Wang, Zhihong J

Armstrong, Amy E; Belzberg, Allan J; Crawford, John R; Hirbe, Angela C; Wang, Zhihong J.

Afiliação

Armstrong AE; Division of Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, MO, USA. armstrongae@wustl.edu.
Belzberg AJ; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Crawford JR; CHOC Neuroscience Institute, Children's Hospital of Orange County, Orange, CA, USA.
Hirbe AC; Department of Pediatrics, Division of Child Neurology University of California Irvine, Orange, CA, USA.
Wang ZJ; Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.

BMC Cancer ; 23(1): 553, 2023 Jun 16.

Article em En | MEDLINE | ID: mdl-37328781

Assuntos

Neurofibroma Plexiforme; Neurofibromatose 1; Criança; Humanos; Neurofibromatose 1/complicações; Neurofibromatose 1/tratamento farmacológico; Neurofibromatose 1/genética; Neurofibroma Plexiforme/tratamento farmacológico; Qualidade de Vida; Inibidores de Proteínas Quinases/uso terapêutico; Quinases de Proteína Quinase Ativadas por Mitógeno

Palavras-chave

Clinical decision making; MEK inhibitors; Neurofibromatosis type 1; Plexiform neurofibroma; Surgery

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neurofibromatose 1 / Neurofibroma Plexiforme Tipo de estudo: Guideline / Prognostic_studies Limite: Child / Humans Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google